Clarapath Raises $36m To Modernize 150-year-old Lab Processes

By Author: Ben Gross
Total Articles: 444
Comment this article

Clarapath, a medical robotics company revolutionizing the processing of tissue in pathology laboratories, has recently secured a $36 million Series B-1 funding round led by Northwell Ventures. Other key investors in this round include CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures, bringing the total funding for the company to $75 million.

Eric Feinstein, the CEO of Clarapath, emphasized the shared mission with strategic investors to transform patient care by modernizing this crucial aspect that has been historically neglected. He highlighted the importance of automation in the early stages of pathology to ensure consistent results and high-quality samples for diagnosis. The company's innovative automation and digital tools aim to gather unprecedented data, ultimately leading to faster results and reduced subjectivity for patients.

Pathology, which involves the microscopic examination of cells and tissues, plays a vital role in the diagnosis and treatment of various diseases such as cancer, autoimmune disorders, and degenerative conditions. With over 12 million biopsies conducted annually in the ...
... US, along with numerous biopharmaceutical safety tests, laboratories are facing challenges due to labor shortages, increasing workloads, and outdated manual processes for sample preparation.

Rich Mulry, the CEO of Northwell Holdings, highlighted the organization's commitment to supporting innovative solutions that enhance patient care and reduce costs. He praised Clarapath for its visionary approach to revolutionizing laboratory medicine and expressed continued support for their journey towards transforming medical diagnostics.

More Information : https://www.techdogs.com/tech-news/business-wire/clarapath-closes-36m-b-round-to-transform-150-year-old-laboratory-processes